BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 222 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $5,188,159 | -8.5% | 839,508 | -24.8% | 0.00% | 0.0% |
Q1 2024 | $5,672,725 | +15.1% | 1,116,678 | +35.7% | 0.00% | 0.0% |
Q4 2023 | $4,929,411 | +12.6% | 822,940 | +33.0% | 0.00% | 0.0% |
Q3 2023 | $4,379,730 | +45.4% | 618,606 | +44.6% | 0.00% | 0.0% |
Q2 2023 | $3,011,572 | +31.5% | 427,780 | +55.8% | 0.00% | 0.0% |
Q1 2023 | $2,289,539 | -32.4% | 274,525 | -6.9% | 0.00% | -50.0% |
Q4 2022 | $3,385,934 | +295.6% | 294,942 | +334.1% | 0.00% | – |
Q3 2022 | $856,000 | -51.4% | 67,939 | -59.2% | 0.00% | -100.0% |
Q2 2022 | $1,762,000 | -89.9% | 166,558 | -84.5% | 0.00% | -83.3% |
Q1 2022 | $17,473,000 | +21.0% | 1,074,635 | +3.0% | 0.01% | +50.0% |
Q4 2021 | $14,446,000 | -21.2% | 1,043,018 | -18.3% | 0.00% | -33.3% |
Q3 2021 | $18,343,000 | -7.1% | 1,276,481 | +2.2% | 0.01% | -25.0% |
Q2 2021 | $19,749,000 | +43.3% | 1,249,076 | -7.8% | 0.01% | +14.3% |
Q1 2021 | $13,785,000 | +175.4% | 1,355,373 | +101.7% | 0.01% | +250.0% |
Q4 2020 | $5,005,000 | +391.7% | 671,860 | +126.7% | 0.00% | – |
Q3 2020 | $1,018,000 | -30.6% | 296,328 | -3.7% | 0.00% | -100.0% |
Q2 2020 | $1,466,000 | +1443.2% | 307,611 | +544.7% | 0.00% | – |
Q1 2020 | $95,000 | +69.6% | 47,714 | +191.5% | 0.00% | – |
Q4 2019 | $56,000 | +16.7% | 16,370 | -2.2% | 0.00% | – |
Q3 2019 | $48,000 | -30.4% | 16,730 | -8.4% | 0.00% | – |
Q2 2019 | $69,000 | -48.9% | 18,271 | -33.7% | 0.00% | – |
Q4 2017 | $135,000 | -71.6% | 27,549 | -67.9% | 0.00% | -100.0% |
Q2 2017 | $476,000 | +336.7% | 85,700 | +559.2% | 0.00% | – |
Q1 2017 | $109,000 | +60.3% | 13,000 | +21.5% | 0.00% | – |
Q4 2016 | $68,000 | -27.7% | 10,700 | -67.9% | 0.00% | -100.0% |
Q1 2016 | $94,000 | -48.1% | 33,348 | +90.2% | 0.00% | 0.0% |
Q4 2015 | $181,000 | -7.2% | 17,537 | +2.6% | 0.00% | 0.0% |
Q3 2015 | $195,000 | +16.8% | 17,100 | -0.1% | 0.00% | -50.0% |
Q3 2014 | $167,000 | -87.7% | 17,114 | -84.0% | 0.00% | -88.2% |
Q2 2014 | $1,361,000 | -28.7% | 106,801 | -40.8% | 0.02% | -19.0% |
Q1 2014 | $1,909,000 | – | 180,460 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |